Craniosynostosis occurs when skull sutures fuse too early, requiring risky surgeries. The researcher identified microRNA-200A as a key regulator of suture development. In mice lacking miR-200A, sutures fused prematurely, but adding extra miR-200A via gene therapy prevented fusion entirely. This breakthrough suggests a non-surgical future treatment for craniosynostosis.

This research tests the safety of a new hypertension drug designed for patients who don’t respond to current medications. Through four phases of pre-clinical toxicology studies in cells and mice, the drug showed no major toxicity and effectively lowered blood pressure, supporting its progression toward future human clinical trials.